심바스타틴과 니카르디핀과의 약동학적 상호작용
Pharmacokinetic Interaction between Simvastatin and Nicardipine
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
The aim of this study was to investigate the effect of simvastatin on the pharmacokinetics of nicardipine in rats. Pharmacokinetic parameters of nicardipine were determined after an oral administration of nicardipine (12 mg/kg) to rats coadministered with simvastatin (0.3 and 1.0 mg/kg). Compared with the control (given nicardipine alone), coadministration of simvastatin (1.0 mg/kg) significantly (p<0.05) increased the area under the plasma concentration (AUC) and peak plasma concentration (Cmax) of nicardipine. The relative bioavailability (RB%) of nicardipine increased from 1.19-to 1.48-fold. However there were no significant changes in tmax, and t1/2 of nicardipine. The enhanced oral bioavailability of nicardipine might be due to an inbition of cytochrom P450 3A mediated-metabolism of nicardipine in the intestine and in the liver by simvastatin. Based on these results, the concurrent use of simvastatin significantly enhanced the oral exposure of nicardipine in rats. The dosage regimen of nicardipine should be taken into consideration for potential drug interaction when combined with simvastatin in clinics.
Abstract
The aim of this study was to investigate the effect of simvastatin on the pharmacokinetics of nicardipine in rats. Pharmacokinetic parameters of nicardipine were determined after an oral administration of nicardipine (12 mg/kg) to rats coadministered with simvastatin (0.3 and 1.0 mg/kg). Compared with the control (given nicardipine alone), coadministration of simvastatin (1.0 mg/kg) significantly (p<0.05) increased the area under the plasma concentration (AUC) and peak plasma concentration (Cmax) of nicardipine. The relative bioavailability (RB%) of nicardipine increased from 1.19-to 1.48-fold. However there were no significant changes in tmax, and t1/2 of nicardipine. The enhanced oral bioavailability of nicardipine might be due to an inbition of cytochrom P450 3A mediated-metabolism of nicardipine in the intestine and in the liver by simvastatin. Based on these results, the concurrent use of simvastatin significantly enhanced the oral exposure of nicardipine in rats. The dosage regimen of nicardipine should be taken into consideration for potential drug interaction when combined with simvastatin in clinics.
참고문헌 (24)
- Kishi Y, "Haemodynamic effects of nicardipine hydrochloride. Studies during its use to control acute hypertension in anaesthetized patients", Br J Anaesth, 56, pp.1003~1007 (1984)
- Hysing ES, "Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. III. Nicardipine and isoflurane", Anaesthesiology, 65, pp.385~391 (1986)
- Van Swieten PA, "Blood Press", 78~90 (1997)
- Graham DJ, "Pharmacokinetics of nicardipine following oral and intravenous administration in man", Postgrad Med J, 4, pp.7~10 (1984)
- Graham DJ, "The metabolism and pharmacokinetics of nicardipine hydrochloride in man", Br J Clin Pharmacol, 1, pp.23~28 (1985)
- Higuchi S, "Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro", Xenobiotica, pp.889~896 (1980)
- Guengerich FP, "Reactions and significance of cytochrome P-450 enzymes", J Biol Chem, 266, pp.10019~10022 (1991)
- Guengerich FP, "Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism", J Biol Chem, 261, pp.5051~5060 (1986)
- Wang EJ, "Two transport binding sites of P-glycoprotein are unequal yet contingent : initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependence", Biochem Biophys Acta, 1481, pp.63~74 (2000)
- Mauro VF, "Simvastatin: a review of its pharmacology and clinical use", DICP, 25, pp.257~264 (1991)
- Schectman G, "Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment", Ann Intern Med, 125, pp.990~1000 (1998)
- Plosker GL, "Simvastatin:a reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia", Drugs, 50, pp.334~363 (1995)
- Lennernäs H, "Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: similarities and differences", Clin Pharmacokinet, 32, pp.403~425 (1997)
- Prueksaritanout T, "In vivo metabolism of simvastatin in human: identification of metabolizing enzymes and effect of the drug on hepatic P450s", Drug Metab Dispos, 25, pp.1191~1199 (1997)
- Cohen LH, "Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes", Biopharm Drug Dispos, 21, pp.353~364 (2000)
- Kirchheiner J, "Clinical consequences of cytochrome P450 2C9 polymorphisms", Clin Pharmacol Ther, 77, pp.1~16 (2005)
- Maura VF, "Clinical pharmacokinetics and practical applications of simvastatin", Clin Pharmacokinet, 24, pp.195~202 (1993)
- Yeo KR, "Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes", Br J Clin Pharmacol, 51, pp.461~470 (2001)
- Watanabe H, "Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension", Life Sci, 76, pp.281~292 (2004)
- Wang EJ, "HMG-Coa reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein", Pharm Res, 18, pp.800~806 (2001)
- Eastwood RJ, "High-performance liquid chromatographic method for the measurement of nicardipine in plasma or serum", J Chromatogr, 530, pp.463~468 (1990)
- Mc Donnell CG, "Effect of atorvastatin and simvastatin on the metabolism of midazolam by cytochrome P450 in vitro", Anaesthesia, 60, pp.747~753 (2005)
- Choi JS, "Pharmacokinetic interaction between fluvastatin and diltiazem in rats", Biopharm Drug Dispos, 27, pp.437~441 (2006)
- Kim DH, "Effect of atrovastatin on the Intravenous and Oral Pharmacokinetics of Verapamil in rats", Biopharm Drug Dispos, 29, pp.45~50 (2008)